The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: essensys loss widens; Carclo demand strong

Tue, 18th Oct 2022 22:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - In year ended July 31, pretax loss widens to GBP11.1 million from GBP2.9 million a year prior. Revenue rises to GBP23.3 million from GBP22.0 million. Administrative expenses grows to GBP24.3 million from GBP16.5 million. Chief Executive Mark Furness says period was a year of "progress and resilience". "Momentum with strategic customers remains and underpins a significant pipeline of opportunities. The quality of our customer base has helped us to manage near-term headwinds such as delays to sales cycles and capital deployment, some portfolio rebalancing among our larger flexible workspace operators and the expected churn at the tail-end of our customer base," he adds.

----------

Carclo PLC - West Yorkshire-based plastic parts manufacturer - Says demand in first six months of its financial year, ending March 31 2023, has been "strong", resulting in sales marginally ahead of board expectations and ahead of the prior year. It adds: "The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Decides to close facilities in Toronto, Canada in an orderly wind down. Notes it retains its high-specification clinical laboratory facility in Plymouth Meeting, Pennsylvania, US, as its central hub for North American activities. Says decision is part of commitment to tightly control costs and focus on near-term commercialisation of Parsortix system for cancer liquid biopsy. Hopes to reduce costs by GBP2.6 million in 2023, rising to GBP4.0 million after.

----------

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Pretax loss in year to June narrows to GBP2.6 million versus GBP2.9 million loss in 15 months to June 30, 2021. Revenue multiplies to GBP4.0 million from GBP1.6 million. Administrative expenses rise to GBP4.4 million from GBP3.1 million. Chief Executive Arron Tolley says: "Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, US and APAC regions." Sees strong revenue growth in current financial year.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Appoints Stephen Pinkerton as chief financial officer, to replace Leo Toole who will step down at end of 2022. Pinkerton is chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017. Also notes Cathal Friel is reverting to Non-Executive Chair after Yamin Khan appointment of chief executive officer.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Dec 2020 11:38

Open Orphan upbeat on progress with nasal Covid-19 vaccine

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Monday that the first in-human study of the Codagenix intranasal SARS-CoV-2 vaccine candidate for Covid-19 had gained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Read more
24 Nov 2020 16:27

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Read more
19 Nov 2020 21:18

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

Read more
5 Nov 2020 16:32

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

Read more
30 Oct 2020 11:30

Open Orphan secures new two-year contract with German client

(Sharecast News) - Pharmaceutical services company Open Orphan announced a new two-year contract with an unnamed tier 1 Germany-based pharmaceutical company on Friday.

Read more
30 Oct 2020 11:07

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Read more
20 Oct 2020 15:59

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

Read more
20 Oct 2020 09:49

Open Orphan to assist UK govt in Covid-19 study

(Sharecast News) - Pharmaceutical services company Open Orphan has signed a contract with the UK Government that will see the firm assist in the development of a Covid-19 human challenge study model to safely speed up the development of an efficacious vaccine.

Read more
16 Oct 2020 15:24

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

Read more
16 Oct 2020 08:57

Open Orphan continues talks over coronavirus challenge study

(Sharecast News) - Open Orphan updated the market on its talks with the UK government and other partners for a coronavirus challenge study in the UK on Friday, confirming that "advanced negotiations" were ongoing.

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
28 Sep 2020 19:34

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

Read more
24 Sep 2020 17:35

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

Read more
22 Sep 2020 19:35

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

Read more
22 Sep 2020 09:43

Open Orphan subsidiary wins 'important' new contract

(Sharecast News) - Pharmaceutical contract research organisation Open Orphan secured an "important" new contract to support an unnamed European client via its French subsidiary, Venn Life Sciences.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.